FDA Warns Another 'Stem Cell' Skin-Care Marketer For Overreaching Claims
This article was originally published in The Rose Sheet
Executive Summary
Stem cell-related claims on cosmetics may capture consumers' imagination, but they seem to be grabbing FDA's attention as well. Hollywood Skincare International, which markets its DermaSet Stem Cell 3D Renewal cream online through a negative billing option, is the latest player in this game to receive a warning letter from the agency.
You may also be interested in...
FDA Warning Cites Ageless Derma's Anti-Wrinkle, Brightening Claims
In a warning letter published on FDA's website May 2, the agency identifies two Ageless Derma products as unapproved new drugs due to label and website claims touting body structure/function effects. The laundry list of offending claims offers a resource for companies to use in their own claims-compliance efforts.
Cosmetics E-tailers At Risk Amid Trending Auto-Renewal Class Actions
Businesses must provide proper disclosures to online consumers who enroll in auto-renewal purchasing or subscription programs or risk facing litigation in California and other states, according to Tucker Ellis attorney Ronie Schmelz. Birchbox is among companies that have been targeted for alleged violations of California law designed to protect consumers from being charged for continuous product shipments or ongoing services without their express consent and ability to cancel easily.
‘Revolution’ Quelled? FDA Warns Firm For ReLuma Stem-Cell Claims
Claims promoting Cell Vitals’ ReLuma skin-care line render the products unapproved drugs, FDA asserts in a Nov. 24 warning letter. Marketed as “A Revolution in Stem Cell Skin Care,” the firm’s products feature cytokines and growth factors harvested from adult stem cells that send “grow and divide” signals to aging skin cells, the company says.